• 13 DE
• 14 EN

• 9 Home
• 10 Contact
• 11 Sitemap

• 7 Press
  • 7.1 Press Releases
    • 7.1.1 Company
      • 7.1.1.1 2000
      • 7.1.1.2 2001
      • 7.1.1.3 2002
      • 7.1.1.4 2003
      • 7.1.1.5 2004
      • 7.1.1.6 2005
      • 7.1.1.7 2006
      • 7.1.1.8 2007
      • 7.1.1.9 2008
    • 7.1.2 Health
  • 7.2 Photos & Logos

Press Releases Company
= Information for professionals with login

2008 | 2007 | 2006 | 2005

2008

• The pharmaceutical company Merz is 100 years old (07 Mar 2008)

• Professor Josef Rauschecker appointed as 18th annual Friedrich Merz Guest Professorship / Prestigious Symposium in Frankfurt (26 Feb 2008)

2007

• Merz Group experiences successful 2006/07 financial year (20 Nov 2007)

• The Expansion Continues: Merz Invests an Additional Million Euro Sum in Dessau (26 Jul 2007)

• Recommendation of Approval for the Merz Botulinum Neurotoxin Typ A in European Countries (20 Jul 2007)

• Merz Pharmaceuticals and Tel Aviv University Become Partners in Novel Drug Technology Development for Treatment of Alzheimer's (10 Jul 2007)

• Merz provides evidential proof of its success in tinnitus study – considerable expansion of the research & development department (05 Jul 2007)

• Merz funded Alois Alzheimer Award 2007 bestowed upon Professor Dr. Agneta Nordberg (15 Jun 2007)

• Merz bets on growth - Hans-Jörg Bergler takes over leadership of the newly created Corporate Development / Mergers & Acquisitions department (04 Jun 2007)

• Alzheimer's medication Memantine exceeds blockbuster mark of 1 billion US dollars (15 May 2007)

• "Change in Merz Group leadership: Professor Scheuble will be leaving the company (23 Apr 2007)

• Frankfurt Biotechnology Innovation Center plans large expansion with Merz Pharma (01 Feb 2007)

2006

• Professor Mauricio Montal appointed as 17th Friedrich Merz visiting professor - Top-class symposium in Frankfurt (21 Nov 2006)

• Merz wins patent dispute with Allergan (30 Oct 2006)

• Bernhard Scheuble appointed as CEO of the MERZ Group (27 Sep 2006)

• Change in Management in Global Research & Development at Merz Pharmaceuticals (24 Jul 2006)

• Merz Pharmaceuticals GmbH acquires presence in United Kingdom with the takeover of Denfleet Pharma Ltd. (09 Jun 2006)

2005

• Merz Pharmaceuticals Taps the Third Largest Pharmaceutical Market in Europe with Merz Italia (20 Oct 2005)

• Merz Pharma awarded certificate for family-friendly personnel policies (05 Sep 2005)

• Alzheimer´s Substance Memantine strenghtens worldwide market position (10 Aug 2005)

• Global Sales of Alzheimer’s Substance Memantine Exceeds 500 Million Euros (10 Aug 2005) 

• Patients with Vascular Dementia Benefit from Treatment with Memantine (13 Jun 2005) 

• New Publication on Alzheimer’s Disease Shows Patients with Behavioral Disturbances Benefit from Axura® (Memantine) (13 May 2005)

• Merz Pharmaceuticals: New Strategic Partnership strenghtens Product Portfolio in Aesthetic Dermatology (12 May 2005)

• Dr. Martin Zügel named Chief Executive Officer of Merz Pharmaceuticals GmbH, effective April 1, 2005 (08 Apr 2005)

• Switching to AXURA® from Acetylcholin-esterase-Inhibitor is safe and well tolerated (14 Mar 2005) 

• 0.1 A-
• 0.2 A
• 0.3 A+
• 0.4 Print

Search

Search

Search

Login for Professionals

Login for Professionals

Merz DocCheck User Password

new user

German Websites

• Alzheimer´s
• Depression
• Dystonia
• Hair Loss
• Hyal-System
• Liver Disease
• Parkinson´s